Opko Health, Inc. (OPK) ended last trading session with a change of -0.38 percent. It trades at an average volume of 5.24M shares versus 2.98M shares recorded at the end of last trading session. The share price of $7.92 is at a distance of 11.08 percent from its 52-week low and down -34.81 percent versus its peak. The company has a market cap of $4.37B and currently has 551.19M shares outstanding. The share price is currently -3.76 percent versus its SMA20, -8.71 percent versus its SMA50, and -18.46 percent versus its SMA200. The stock has a weekly performance of 4.07 percent and is -14.84 percent year-to-date as of the recent close.
March 01, 2017 — OPKO Health, Inc. (OPK) reports financial and operating results for the three months ended December 31, 2016.
- Consolidated revenues for the three months ended December 31, 2016 of $275.5 million were consistent with the comparable period of 2015 revenue of $276.2 million. The 2016 period benefited from increased revenue from services at BioReference of $12.8 million, which was offset by a non-recurring $15.0 million milestone payment that was received during the comparable period of 2015 related to Varubi™.
- Net loss for the three months ended December 31, 2016 was $13.7 million compared with net income of $1.6 million for the 2015 period. The three months ended December 31, 2016 included the launch related activities for RAYALDEE, including the 50 person commercial organization. Net (loss) income during the three month periods include significant non-recurring and non-cash activities:
– During the three months ended December 31, 2015, revenue included a $15.0 million milestone payment related to the first commercial sale of Varubi™ by TESARO.
– Other income and (expense) was $7.7 million and ($15.9) million in the 2016 and 2015 periods, respectively, primarily related to the change in fair value of derivative instruments. The change in fair value is principally related to an embedded derivative in OPKO’s January 2013 convertible senior notes due in 2033. The 2015 period also included a ($7.3) million temporary impairment charge of an available for sale investment.
Threshold Pharmaceuticals, Inc. (THLD) recently recorded 10.22 percent change and currently at $0.66 is 120.43 percent away from its 52-week low and down -55.32 percent versus its peak. It has a past 5-day performance of 8.41 percent and trades at an average volume of 788.33K shares. The stock has a 1-month performance of 10.22 percent and is 50.3 percent year-to-date as of the recent close. There were about 71M shares outstanding which made its market cap $46.95M. The share price is currently 6.23 percent versus its SMA20, 19.33 percent versus its SMA50, and 9.41 percent versus its SMA200.
January 26, 2017 — Stock-Callers.com explores the Biotech industry to see how some equities have been faring. Under evaluation are: OncoGenex Pharmaceuticals Inc. (OGXI), INSYS Therapeutics Inc. (INSY), Threshold Pharmaceuticals Inc. (THLD), and AmpliPhi Biosciences Corp. (NYSE MKT: APHB). These companies belong to the Healthcare sector which reversed several days of declines on Wednesday, January 25th, 2017, with the NYSE Health Care Index rising over 0.8%, while shares of health care companies in the S&P 500 were up more than 0.9% as a group.